Attached files

file filename
EX-99.1 - EX-99.1 - ALBIREO PHARMA, INC.d301809_ex99-1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

______________


FORM 8-K


CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



Date of report (Date of earliest event reported): January 29, 2016

 

BIODEL INC.

(Exact name of registrant as specified in its charter)



Commission File Number 001-33451

 

     
Delaware
(State or other jurisdiction of incorporation or organization)
  90-0136863
(IRS Employer Identification Number)
     

100 Saw Mill Road

Danbury, Connecticut

(Address of principal executive offices)

 

 

06810

(Zip code)



(203) 796-5000
(Registrant's telephone number, including area code)



Not Applicable


(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 


 

Item 2.02    Results of Operations and Financial Condition

 

On January 29, 2016, Biodel Inc. (the“Company”) issued a press release (the “Press Release”) announcing certain financial information for its first quarter in fiscal year 2016 ended December 31, 2015. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information contained in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act except as expressly set forth by specific reference in such a filing.

 

 

Item 9.01    Financial Statements and Exhibits.

 

(d)               Exhibits.

 

The following exhibit relating to Item 2.02 shall be deemed to be furnished and not filed:

 

99.1 Press Release issued by the Company on January 29, 2016.

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date:  January 29, 2016 BIODEL INC.
   
   
  By: /s/ Paul S. Bavier
    Paul S. Bavier, General Counsel

 


 

EXHIBIT INDEX

 

Exhibit No. Description
   
99.1 Press Release issued by the Company on January 29, 2016.